$GRTSQ
Gritstone bio, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021895 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $4.262M $3.021M $2.614M
YoY Change 39.1% 15.57% 178.38%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.761M $6.462M $6.373M
YoY Change 1.18% 1.4% 26.7%
% of Gross Profit
Research & Development $29.42M $26.44M $24.40M
YoY Change 12.44% 8.36% 10.64%
% of Gross Profit
Depreciation & Amortization $1.791M $1.676M $1.589M
YoY Change 14.44% 5.48% -4.85%
% of Gross Profit
Operating Expenses $36.18M $32.90M $30.77M
YoY Change 10.15% 6.92% 13.62%
Operating Profit -$29.88M -$28.16M
YoY Change 6.12% 7.7%
Interest Expense $629.0K $551.0K $37.00K
YoY Change 4093.33% 1389.19% -46.38%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$31.29M -$29.97M -$28.12M
YoY Change 5.11% 6.57% 7.86%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$31.29M -$29.97M -$28.12M
YoY Change 5.11% 6.57% 7.84%
Net Earnings / Revenue -734.16% -991.92% -1075.67%
Basic Earnings Per Share -$0.35 -$0.36
Diluted Earnings Per Share -$0.36 -$0.35 -$361.5K
COMMON SHARES
Basic Shares Outstanding 83.37M 73.01M 77.78M
Diluted Shares Outstanding 86.60M 77.78M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $175.9M $139.8M $199.7M
YoY Change -14.73% -29.98% 183.23%
Cash & Equivalents $55.50M $64.91M $131.4M
Short-Term Investments $120.4M $74.90M $68.26M
Other Short-Term Assets $567.0K $796.0K $814.0K
YoY Change -34.53% -2.21% 101.99%
Inventory
Prepaid Expenses
Receivables $0.00 $1.096M
Other Receivables $529.0K $0.00
Total Short-Term Assets $182.9M $153.4M $218.4M
YoY Change -17.1% -29.75% 196.34%
LONG-TERM ASSETS
Property, Plant & Equipment $21.34M $21.67M $21.34M
YoY Change -1.33% 1.57% -8.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.031M $0.00
YoY Change -12.69%
Other Assets $15.03M $10.82M $7.751M
YoY Change 79.84% 39.62% 187.07%
Total Long-Term Assets $57.88M $51.82M $52.88M
YoY Change 0.63% -2.02% 8.36%
TOTAL ASSETS
Total Short-Term Assets $182.9M $153.4M $218.4M
Total Long-Term Assets $57.88M $51.82M $52.88M
Total Assets $240.8M $205.2M $271.3M
YoY Change -13.43% -24.34% 121.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.694M $2.885M $3.393M
YoY Change 105.53% -14.97% 2.82%
Accrued Expenses $4.124M $2.670M $3.022M
YoY Change 903.41% -11.65% -77.11%
Deferred Revenue $5.131M $8.688M $13.79M
YoY Change -70.17% -36.98%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.80M $32.31M $36.31M
YoY Change -12.9% -11.02% 65.06%
LONG-TERM LIABILITIES
Long-Term Debt $19.35M $19.28M $0.00
YoY Change
Other Long-Term Liabilities $150.0K $49.00K $395.0K
YoY Change -87.59% -98.61%
Total Long-Term Liabilities $19.50M $19.33M $395.0K
YoY Change 4793.67% -98.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.80M $32.31M $36.31M
Total Long-Term Liabilities $19.50M $19.33M $395.0K
Total Liabilities $69.97M $68.40M $63.33M
YoY Change 12.82% 8.0% 25.4%
SHAREHOLDERS EQUITY
Retained Earnings -$521.1M -$489.8M -$371.6M
YoY Change 29.82% 31.81% 24.24%
Common Stock $22.00K $20.00K $20.00K
YoY Change 10.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $170.8M $136.8M $208.0M
YoY Change
Total Liabilities & Shareholders Equity $240.8M $205.2M $271.3M
YoY Change -13.43% -24.34% 121.45%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$31.29M -$29.97M -$28.12M
YoY Change 5.11% 6.57% 7.84%
Depreciation, Depletion And Amortization $1.791M $1.676M $1.589M
YoY Change 14.44% 5.48% -4.85%
Cash From Operating Activities -$30.37M -$25.78M -$14.87M
YoY Change 27.73% 73.38% -26.31%
INVESTING ACTIVITIES
Capital Expenditures $1.483M -$1.124M -$1.473M
YoY Change -211.5% -23.69% 141.48%
Acquisitions
YoY Change
Other Investing Activities -$44.67M $4.199M $42.63M
YoY Change -1.38% -90.15% 160.75%
Cash From Investing Activities -$46.15M $3.075M $41.16M
YoY Change -1.02% -92.53% 161.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 64.36M 19.34M 56.74M
YoY Change 95.78% -65.92% 141757.5%
NET CHANGE
Cash From Operating Activities -30.37M -25.78M -14.87M
Cash From Investing Activities -46.15M 3.075M 41.16M
Cash From Financing Activities 64.36M 19.34M 56.74M
Net Change In Cash -12.16M -3.369M 83.03M
YoY Change -67.59% -104.06% -1982.81%
FREE CASH FLOW
Cash From Operating Activities -$30.37M -$25.78M -$14.87M
Capital Expenditures $1.483M -$1.124M -$1.473M
Free Cash Flow -$31.86M -$24.66M -$13.40M
YoY Change 41.91% 84.06% -31.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-942000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-217000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-216000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1543000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
106000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-208000
grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1331000
grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1487000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
7000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
7000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4859534
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
2313000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
553000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
109000
grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
1406000
grts Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification
RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
6453000
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001656634
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21672000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38663
dei Entity Registrant Name
EntityRegistrantName
Gritstone bio, Inc.
CY2021Q4 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3706000
dei Entity Address Address Line1
EntityAddressAddressLine1
5959 Horton Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
871-6100
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
GRTS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83366277
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64909000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93287000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
74900000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
108346000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
6727000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
11285000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6891000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7672000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
153427000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
220590000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5290000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6005000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21622000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19321000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22920000
CY2022Q3 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
5532000
CY2021Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2352000
CY2022Q3 grts Long Term Marketable Securities
LongTermMarketableSecurities
0
CY2021Q4 grts Long Term Marketable Securities
LongTermMarketableSecurities
4617000
CY2022Q3 us-gaap Assets
Assets
205242000
CY2021Q4 us-gaap Assets
Assets
278106000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2885000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4230000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6708000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6925000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2670000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
411000
CY2022Q3 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5037000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3021000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6325000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7483000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8688000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17201000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32313000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39956000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
49000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16752000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18936000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3128000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19281000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
68395000
CY2021Q4 us-gaap Liabilities
Liabilities
62020000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73134051
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73134051
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69047878
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69047878
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
20000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
626889000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
617523000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-281000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-73000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-489781000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401384000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
136847000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
216086000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
205242000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278106000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2614000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15683000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
129000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-7000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77775497
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45150000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26436000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24396000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81983000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71324000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6462000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6373000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22209000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19251000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
32898000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
30769000
us-gaap Operating Expenses
OperatingExpenses
104192000
us-gaap Operating Expenses
OperatingExpenses
90575000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29877000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28155000
us-gaap Operating Income Loss
OperatingIncomeLoss
-88509000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45425000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
462000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
37000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
663000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
112000
CY2022Q3 us-gaap Interest Expense
InterestExpense
551000
CY2021Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
551000
us-gaap Interest Expense
InterestExpense
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29966000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28118000
us-gaap Net Income Loss
NetIncomeLoss
-88397000
us-gaap Net Income Loss
NetIncomeLoss
-45313000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29837000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28125000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88605000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45306000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86597405
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86597405
us-gaap Net Income Loss
NetIncomeLoss
-45313000
us-gaap Interest Paid Net
InterestPaidNet
208000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77775497
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1174000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86441212
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86441212
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3180000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
327000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76837503
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76837503
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
163378000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3064000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
129000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29966000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
136847000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
178825000
CY2021Q3 grts Issuance Of Common Stock For Warrant Exercises Value
IssuanceOfCommonStockForWarrantExercisesValue
40000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1062000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2819000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-7000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28118000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
207955000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
216086000
grts Issuance Of Common Stock For Warrant Exercises Value
IssuanceOfCommonStockForWarrantExercisesValue
34000
grts Tax Payments Related To Shares Withheld For Vested Restricted Stock Units
TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits
-890000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
145000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
331000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9549000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-208000
us-gaap Net Income Loss
NetIncomeLoss
-88397000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
136847000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
166739000
grts Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants
AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants
-451000
grts Stock Issued During Period Value Purchase Agreement
StockIssuedDuringPeriodValuePurchaseAgreement
20830000
grts Issuance Of Common Stock For Warrant Exercises Value
IssuanceOfCommonStockForWarrantExercisesValue
40000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3108000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
279000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7753000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
207955000
us-gaap Net Income Loss
NetIncomeLoss
-88397000
us-gaap Net Income Loss
NetIncomeLoss
-45313000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4769000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4782000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-278000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-549000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
127000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
us-gaap Share Based Compensation
ShareBasedCompensation
9549000
us-gaap Share Based Compensation
ShareBasedCompensation
7753000
grts Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
6891000
grts Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
5743000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-781000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3484000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
199000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-943000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-6463000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
2000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26900000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-489800000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-5902000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11641000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8865000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85572000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26899000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
64641000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
133409000
grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
102218000
grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
59390000
grts Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0
grts Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
6225000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4389000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4133000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33188000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71927000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
19154000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
115000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
6026000
grts Payments Of Financing Lease
PaymentsOfFinancingLease
171000
grts Payments Of Financing Lease
PaymentsOfFinancingLease
-0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
890000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18733000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75883000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33651000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22943000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110577000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171048000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76926000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148105000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-30000000.0
us-gaap Net Income Loss
NetIncomeLoss
-88400000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28100000
us-gaap Net Income Loss
NetIncomeLoss
-45300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85600000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401400000
CY2022Q3 grts Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
139800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the condensed consolidated balance sheets. As of September 30, 2022, the Company has no off-balance sheet concentrations of credit risk.</span></p>
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2021Q3 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64909000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93287000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
6727000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
11285000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5290000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6005000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
76926000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110577000
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2020Q2 grts Use Of Net Operating Losses Suspension Period For Medium And Large Business
UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness
P3Y
CY2020Q2 grts Use Of Business Incentive Tax Credits Period Cap
UseOfBusinessIncentiveTaxCreditsPeriodCap
P3Y
CY2022Q3 grts Collaboration Receivable
CollaborationReceivable
291000
CY2021Q4 grts Collaboration Receivable
CollaborationReceivable
688000
grts Fair Value Measurement Level1 To Level2 Transfers
FairValueMeasurementLevel1ToLevel2Transfers
0
grts Fair Value Measurement Level1 To Level2 Transfers
FairValueMeasurementLevel1ToLevel2Transfers
0
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
46355000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
41907000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27018000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22276000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
52000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1769000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
117086000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
281000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
116805000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
194348000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
73000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
194275000
grts Marketable Securities Realized Gain Loss Description
MarketableSecuritiesRealizedGainLossDescription
no material realized gains or losses
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
grts Period Of Unrealized Loss Position
PeriodOfUnrealizedLossPosition
12 months or greater
CY2022Q3 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21672000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21622000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4800000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4800000
CY2022Q3 grts Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
62812000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
108088000
CY2022Q3 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
529000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
2112000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1922000
us-gaap Operating Lease Cost
OperatingLeaseCost
6633000
us-gaap Operating Lease Cost
OperatingLeaseCost
5743000
CY2022Q3 us-gaap Lease Cost
LeaseCost
2112000
CY2021Q3 us-gaap Lease Cost
LeaseCost
1922000
us-gaap Lease Cost
LeaseCost
6633000
us-gaap Lease Cost
LeaseCost
5743000
us-gaap Operating Lease Payments
OperatingLeasePayments
6467000
us-gaap Operating Lease Payments
OperatingLeasePayments
5902000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1959000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6562000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.073
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2523000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9192000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12527000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10658000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
10376000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5310000
CY2022Q3 grts Operating Lease Payment Under The Boston Lease
OperatingLeasePaymentUnderTheBostonLease
79701000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
23077000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6325000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16752000
CY2022Q3 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
4839000
CY2021Q4 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
2672000
CY2022Q3 grts Net Contract Asset
NetContractAsset
0
CY2021Q4 grts Net Contract Asset
NetContractAsset
1385000
CY2021Q4 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
292000
CY2022Q3 grts Facilities Related Deposits
FacilitiesRelatedDeposits
384000
CY2021Q4 grts Facilities Related Deposits
FacilitiesRelatedDeposits
0
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
796000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
866000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6891000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7672000
CY2022Q3 us-gaap Security Deposit
SecurityDeposit
934000
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
1305000
CY2022Q3 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
1123000
CY2021Q4 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
1047000
CY2022Q3 us-gaap Prepaid Rent
PrepaidRent
3475000
CY2021Q4 us-gaap Prepaid Rent
PrepaidRent
0
CY2022Q3 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
5532000
CY2021Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2352000
CY2022Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2022Q3 grts Final Fee
FinalFee
1150000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-1869000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
19281000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
7092000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
7712000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive
5196000
CY2022Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1169591
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73134051
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73134051
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69047878
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69047878
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s common stock are entitled to one vote per share.
CY2019Q4 grts Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
250000000.0
CY2022Q1 grts Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
250000000.0
grts Class Of Warrant Or Right Issue Date
ClassOfWarrantOrRightIssueDate
2020-12-28
grts Class Of Warrant Or Rights Expiration
ClassOfWarrantOrRightsExpiration
None
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13573704
grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
3442567
CY2021Q3 grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
0
grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
700000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3459187
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5107335
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.82
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M17D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17153000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
3461915
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted
3289384
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2939211
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.88
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
140000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.03
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled
1054304
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
911676
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.61
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4686022
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6994870
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M19D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
532000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3008491
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
9.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y2M26D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
354000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6400481
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M20D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
504000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5400000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
15900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2600000
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
500000
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
500000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
708800
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
350173
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
353300
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
5.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
142628
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
5.35
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
563045
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.38
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7680130
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5281474
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3064000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2819000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9549000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7753000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29966000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28118000
us-gaap Net Income Loss
NetIncomeLoss
-88397000
us-gaap Net Income Loss
NetIncomeLoss
-45313000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86597405
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86597405
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77775497
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77775497
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86441212
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86441212
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76837503
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76837503
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-22-021895-index-headers.html Edgar Link pending
0000950170-22-021895-index.html Edgar Link pending
0000950170-22-021895.txt Edgar Link pending
0000950170-22-021895-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grts-20220930.htm Edgar Link pending
grts-20220930.xsd Edgar Link pending
grts-ex10_1.htm Edgar Link pending
grts-ex31_1.htm Edgar Link pending
grts-ex31_2.htm Edgar Link pending
grts-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
grts-20220930_cal.xml Edgar Link unprocessable
grts-20220930_def.xml Edgar Link unprocessable
grts-20220930_pre.xml Edgar Link unprocessable
grts-20220930_lab.xml Edgar Link unprocessable
grts-20220930_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending